CHICAGO /PRNewsSpreader/ -- Shamital Corp. announced today that the Food and Drug Administration has granted approval of BilgonX™. This first-of-its-kind technology is being hailed as a breakthrough in the Marketing and PR Industry.
Brenda Verbosae, Vice President and Head of Oncology at Shamital said, " BilgonX™ offers great hope to thousands of agencies, clients and their families. We look forward to a similar outcome in a number of other countries, where regulatory reviews are presently underway. It is our hope to make this important new treatment available to patients suffering from the devastating consequences of invoiceitis."
Invoiceitis is the life-threatening condition clients experience when reviewing their monthly bill. Sufferers of Common Invoiceitis and Complex Invoiceitis report experiencing: hypervigilance (feels like but is not paranoia); exaggerated startle response; irritability; sudden angry or violent outbursts; flashbacks, nightmares, intrusive recollections, replays, violent visualizations; triggers; sleep disturbance; exhaustion and chronic fatigue; reactive depression; guilt; feelings of detachment; avoidance behaviors; nervousness, anxiety; phobias about specific daily routines, events or objects; irrational or impulsive behavior; loss of interest; loss of ambition; anhedonia (inability to feel joy and pleasure); poor concentration; impaired memory; joint pains, muscle pains; emotional numbness; physical numbness; low self-esteem; and an overwhelming sense of injustice and a strong desire to do something about it.
BilgonX™ is a non-selective beta blocker mainly used in the treatment of hypertension. Originally developed to treat hemorrhoids and diverticulitis, its effect on the hormone adrenaline has made it popular among actors dealing with severe stage fright. Now scientists are now using it in their research on memory. In recent years researchers have discovered that certain drugs can interrupt the memory process and frustrate the “consolidation” of a traumatic event. Researchers found that not only does the drug address the symptoms of post traumatic stress, if applied directly it can specifically help clients manage everything from regular monthly heavy-flow bleeding to huge unexplainable billing spikes.
Shamital Corp. is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top drug companies in the world with healthcare sales of over $17 gazillion and leading positions in sales of gastrointestinal, oncology, anaesthesia (including pain management), cardiovascular, central nervous system (CNS) and respiratory products.